Actoxumab
Based on 1 Customer Validation
Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.52%
- No. CAS: 1245634-25-6
- Peso molecular:145 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Clostridioides difficile
IC50 & Target
ToxA
In Vitro
Actoxumab (10 mg/kg WT or N297Q mutant (N297Q) actoxumab-bezlotoxumab; 2 h plus 24 h) significantly inhibits cell rounding activity in Vero cells under 2 ng/mL TcdA treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Actoxumab shows a synergy with Bezlotoxumab, and (combination dosage of 3, 30, 300 μg/mouse; i.p.; single dose) prevents both epithelial damage and inflammatory disease[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Murine C. difficile infection model in CD1 and C57BL/6 mice (6-8 weeks old)[1]
-
Dosage:Combination dosage of 3, 30, 300 μg/mouse; or ~0.1, 1, and 10 mg/kg
-
Administration:Intraperitoneal injection; single dose; 1 hour before 25 ng TcdA or 25 ng TcdB challenge
-
Result:Protected with Bezlotoxumab, against systemic and intestinal toxin challenge in mice.
-
Animal Model:Ileal loop model in CD1 and C57BL/6 mice (6-8 weeks old)[1]
-
Dosage:50 mg/kg; or combined with 50 mg/kg Bezlotoxumab
-
Administration:Intraperitoneal injection; single dose
-
Result:Significantly reduced fluid accumulation in toxin-challenged mice (109.4 mg/cm).
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 1245634-25-6
-
Appearance Liquid
-
Peso molecular 145 kDa
-
Color Colorless to light yellow
-
SMILES
[Actoxumab]
-
Synonyms
Anti-C. difficile Toxin A Recombinant Antibody
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Actoxumab Related Classifications
HY-P99277 Related Classifications
Powered by Bioz